natgillin/translations-raw huggingface dataset:
Fibroplastisk (modent fibrosarkom, myksofibrosarkom, skleroserende epiteloid fibrosarkom, maligne solitære fibrøse tumorer), såkaldt fibrohistiocytiske (pleomorfisk malignt fibrøst histiocytom [MFH], gigantcelle MFH, inflammatorisk MFH), leiomyosarkom, maligne glomus-tumorer, tværstribet muskulatur (pleomorf og alveolært rabdomyosarkom), vaskulær (epiteloid hæmangioendoteliom, angiosarkom), uvis differentiering (synovial, epiteloid, alveolært bløddels, clear cell, desmoplastisk small round cell, ekstra-renal rabdoid, malignt mesenkymom, PECom, intimal sarkom), maligne perifere nerveskede-tumorer, udifferentieret bløddelssarkom ikke specificeret andetsteds (NOS) og andre sarkomtyper (ikke angivet som uegnede).
Fibroblastic (adult fibrosarcoma, myxofibrosarcoma, sclerosing epithelioid fibrosarcoma, malignant solitary fibrous tumours), so-called fibrohistiocytic (pleomorphic malignant fibrous histiocytoma [MFH], giant cell MFH, inflammatory MFH), leiomyosarcoma, malignant glomus tumours, skeletal muscles (pleomorphic and alveolar rhabdomyosarcoma), vascular (epithelioid hemangioendothelioma, angiosarcoma), uncertain differentiation (synovial, epithelioid, alveolar soft part, clear cell, desmoplastic small round cell, extra-renal rhabdoid, malignant mesenchymoma, PEComa, intimal sarcoma), malignant peripheral nerve sheath tumours, undifferentiated soft tissue sarcomas not otherwise specified (NOS) and other types of sarcoma (not listed as ineligible).
Fibroscan, acoustic radiation force impulse (ARFI) eller magnetisk resonans (MR)-elastograf
Fibroscan, acoustic radiation force impulse (ARFI), or magnetic resonance (MR) elastography
Fibroscan, acoustic radiation force impulse (ARFI) eller magnetisk resonans (MR)-elastografi
Fibroscan, acoustic radiation force impulse (ARFI), or magnetic resonance (MR) elastography
Fibroscan, acoustic radiation force impulse (ARFI) eller magnetisk resonans (MR)-elastografi
Fibroscan, acoustic radiation force impulse (ARFI), or magnetic resonance (MR) elastography;
fibrose omkring injektionsstedet, smerter
injection site fibrosis, pain
Fibrose score
Fibrosis Score
Fibrose-score
Fibrosis score
FibroTest-bestemt Metavir-scoreb
FibroTest-Determined Metavir scoreb
Fidaxomicin bør anvendes med forsigtighed hos disse patienter på grund af risiko for øget absorption og potentiel risiko for systemiske bivirkninger.
Fidaxomicin should be used with caution in these patients due to the risk of enhanced absorption and potential risk of systemic adverse reactions.
Fidaxomicin har en MIC90 på 0,25 mg/L, hvorimod C.difficile og den primære metabolit, OP-1118 har en MIC90 på 8 mg/L. Gram-negative organismer er ikke modtagelige over for fidaxomicin.
Fidaxomicin has an MIC90 of 0.25 mg/L versus C. difficile, and its main metabolite, OP-1118, has an MIC90 of 8 mg/L. Gram negative organisms are intrinsically not susceptible to fidaxomicin.
Fiebre
Fever
Fiebre o escalofríos.
Fever or chills
Figur 1
Figure 3
Figur 1
See picture 1.
Figur 1 - Kaplan-Meier PFS-kurve i pNET fase 3-Studiet
Figure 1 - Kaplan-Meier curve of PFS in the pNET Phase 3 Study
Figur 1 A Figur 1B Figur 1C
Figure 1 A Figure 1B Figure 1C
Figur 1 Andelen af ACR 20/50/70-personer, der responderede til og med uge 52 i den samlede analyse af studie PALACE 1, PALACE 2 ogPALACE 3 (NRI*)
Figure 1 Proportion of ACR 20/50/70 responders through Week 52 in the pooled analysis of studies PALACE 1, PALACE 2 and PALACE 3 (NRI*)
Figur 1 Figur 2 Figur 3
Figure 1 Figure 2 Figure 3
Figur 1 Kaplan-Meier estimater af IRC-vurderet PFS
Figure 1 Kaplan-Meier Estimates of IRC-Assessed PFS
Figur 1 Kaplan-Meier kurver for samlet overlevelse (intent-to-treat population)
Figure 1 Kaplan-Meier curves for overall survival (intent-to-treat population)
Figur 1 Kaplan-Meier kurver over den endelige samlede overlevelse – intent-to-treat- population (cut-off dato: 28. august 2015)
Figure 1 Kaplan-Meier curves of final overall survival – Intent to treat population (cut-off date: 28 August 2015)
Figur 1 Kaplan-Meier-afbildning af progressionsfri overlevelse
Figure 1 Kaplan-Meier Plot of Progression-Free Survival
Figur 1 Kaplan-Meier-endepunkts-estimater for primær recidivfri overlevelse (ITT- population)
Figure 1 Kaplan-Meier estimates for primary recurrence-free survival endpoint (ITT population)
Figur 1 Kaplan-Meier-estimater af første morbiditets-mortalitetshændelse
Figure 1 Kaplan-Meier estimates of the first morbidity-mortality event
Figur 1 Kaplan-Meier-kurve for samlet overlevelse, IMPACT-studiet
Figure 1 Kaplan-Meier overall survival curve, IMPACT study
Figur 1 Kaplan-Meier-kurve over progressionsfri overlevelse ved recidiveret myelomatosea
Figure 1 Kaplan-Meier curve of progression-free survival in relapsed multiple myelomaa
Figur 1 Kaplan-Meier-kurver for total overlevelse (intent-to-treat population)
Figure 1 Kaplan-Meier curves for overall survival ( intent-to-treat population)
Figur 1 Middelændring i synsstyrke fra udgangsværdi til måned 24 i studie FVF2598g (MARINA) og studie FVF2587g (ANCHOR)
Figure 1 Mean change in visual acuity from baseline to Month 24 in study FVF2598g (MARINA) and study FVF2587g (ANCHOR)
Figur 1 ovenfor viser virkningsprofilen over tid for insulin glargin og NPH insulin.
Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin.
Figur 1 Studie 19: Kaplan-Meier-plot af PFS for BRCA-muterede patienter (53 % modenhed - investigators vurdering)
Figure 1 Study 19: Kaplan-Meier plot of PFS in BRCA-mutated patients (53% maturity-investigator assessment)
Figur 1 Tidsforløb for procentvis ændring fra udgangsværdi for gennemsnitlig PASI-score i studie 1 (ERASURE)
Figure 1 Time course of percentage change from baseline of mean PASI score in Study 1 (ERASURE)
Figur 1 viser et Kaplan Meier-plot af tid til recidiv iht. behandlingsgruppe.
A Kaplan Meier plot of time to relapse by treatment group is shown in Figure 1.
Figur 1 viser hvordan den fyldte injektionssprøjte ser ud.
Figure 1 shows what the pre-filled syringe looks like.
Figur 1 – Analyse af det primære kliniske sammensatte endepunkt for CV-dødsfald, MI og apopleksi (PLATO)
Figure 1 – Analysis of primary clinical composite endpoint of CV death, MI and stroke (PLATO)
Figur 1 – Relative risiko-(dronedaron 400 mg to gange daglig versus placebo) estimater med 95 % konfidensintervaller ud fra udvalgte baselinekarakteristika – første hospitalsindlæggelse af kardiovaskulære årsager, eller død af vilkårlig årsag.
Figure 1 - Relative risk (dronedarone 400 mg twice daily versus placebo) estimates with 95% confidence intervals according to selected baseline characteristics - first cardiovascular hospitalisation or death from any cause.
Figur 1 – Revertering af dabigatran-induceret forhøjede koagulationsparametre udtrykt som dTT hos 90 patienter fra RE-VERSE AD-studiet
Figure 1 – Reversal of dabigatran-induced clotting time prolongation determined by dTT in 90 patients from the RE-VERSE AD study
Figur 1 – Tid indtil første forekomst af kardiovaskulært dødsfald, MI og apopleksi (PLATO)
Figure 1 – Time to first occurrence of CV death, MI and Stroke (PLATO)
Figur 1- Kaplan-Meier kurve for samlet overlevelse
Figure 1- Kaplan-Meier curves of overall survival
Figur 1.
0.0074
Figur 1: Aktivitetsprofil for NovoMix 30 ( ) og bifasisk humant insulin 30 (---) hos raske personer.
Figure 1: Activity profile of NovoMix 30 ( ) and biphasic human insulin 30 (---) in healthy subjects.
Figur 1: Andel af patienter, der opnåede en normalisering af VMA frem til dag 180 (måned 6) (TG-MV-006, TG-MV-007 og integrerede data)
Figure 1: Proportion of patients with VMA resolution up to Day 180 (Month 6) (TG-MV-006, TG-MV-007 and integrated data)
Figur 1: Antal patienter kategoriseret efter anfaldsrespons over 12 uger for brivaracetam og placebo på tværs af alle tre dobbeltblinde pivotale studier
Figure 1: Proportion of patients by category of seizure response for brivaracetam and placebo over 12 weeks across all three double-blind pivotal trials
Figur 1: Forest plot: Analyse af hver individuel kardiovaskulær hændelse –ITT population
Figure 1: Forest plot: analyses of each individual cardiovascular event -- ITT population
Figur 1: Gennemsnitlig procentuel ændring fra udgangsværdien af LDL-C i hovedundersøgelsen af virkning UP1002/AEGR-733-005 til og med uge 26 (det primære endepunkt) med LOCF for hver parameter (N=29)
Figure 1: Mean percent changes from baseline in LDL-C in the major effectiveness study UP1002/AEGR-733-005 through Week 26 (the Primary Endpoint) using LOCF to each assessment (N=29)
Figur 1: Gennemsnitlig ugentlig score for sværhedsgrad af kløe over tid, studie 1 (mITT population)
Figure 1: Mean weekly itch severity score over time, study 1 (mITT population)
Figur 1: Gennemsnitligt ( standardfejl) asparaginniveau i serum i løbet af induktionsfasen i Studie 1
Figure 1: Mean ( standard error) serum asparagine during Study 1 induction phase
Figur 1: Kaplan Meier kurver af radiografisk progressionsfri overlevelse hos patienter, der er behandlet med enten ZYTIGA eller placebo i kombination med prednison eller prednisolon plus LHRH-analoger eller tidligere orkiektomi
Figure 1: Kaplan Meier curves of radiographic progression-free survival in patients treated with either ZYTIGA or placebo in combination with prednisone or prednisolone plus LHRH analogues or prior orchiectomy
Figur 1: Kaplan-Meier-afbildning af tid til recidiv – endelig analyse
Figure 1: Kaplan-Meier plot of time to relapse – Final analysis
Figur 1: Kaplan-Meier-kurve for samlet overlevelse for patienter med adenokarcinom- tumorhistologi efter behandlingsgruppe i LUME-Lung 1 studiet
Figure 1: Kaplan-Meier curve for overall survival for patients with adenocarcinoma tumour histology by treatment group in trial LUME-Lung 1
Figur 1: Kaplan-Meier-kurve som illustrerer den progressionsfrie overlevelse bedømt ved en uafhængig vurdering af den samlede patientpopulation (behandlingsnaiv population og cytokin-behandlet population) (VEG105192)
Figure 1: Kaplan-Meier curve for progression-free survival by independent assessment for the overall population (treatment-naïve and cytokine pre-treated populations) (VEG105192)
Figur 1: Kaplan-Meier-kurver for progressionsfri overlevelse (ITT-population) i MCL3001- studiet
Figure 1: Kaplan-Meier curve of progression-free survival (ITT Population) in Study MCL3001
Figur 1: Kaplan-Meier-kurver for samlet overlevelse baseret på opdateret overlevelsesanalyse i PREVAIL-studiet (intent-to-treat-analyse)
Figure 1: Kaplan-Meier Overall Survival Curves Based on Updated Survival Analysis in the PREVAIL Study (Intent-to-Treat Analysis)
Figur 1: Kaplan-Meier-kurver for samlet overlevelse i hver behandlingsarm i KEYNOTE-006 (intent to treat-population)
Figure 1: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-006 (intent to treat population)
Figur 1: Middelværdi for observeret ændring i FCV over tid fra baseline (ml), samlet for studierne INPULSIS-1 og INPULSIS-2
Figure 1: Mean (SEM) observed FVC change from baseline (mL) over time, studies INPULSIS-1 and INPULSIS-2 pooled
Figur 1: Profil af median serumkoncentration af lipegfilgrastim og median ANC hos kemoterapi- behandlede patienter efter en enkelt 6 mg injektion af lipegfilgrastim
Figure 1: Profile of median serum concentration of lipegfilgrastim and median ANC in chemotherapy-treated patients after a single 6 mg injection of lipegfilgrastim
Figur 1: Progressionsfri overlevelse
Figure 1: Progression free survival
Figur 1: Tid til 6-måneders vedvarende akkumulering af funktionstab (SAD) i Studie 2
Figure 1: Time to 6-month Sustained Accumulation of Disability in Study 2
Figur 1: Tid til første forekomst af CV-død, MI, apopleksi eller UCR hos post-MI- og PAD- patienter uden apopleksi eller TCI i anamnesen
Figure 1: Time to First Occurrence of CV death, MI, Stroke or UCR in Post-MI or PAD Patients with No History of Stroke or TIA
Figur 1: Tid til første forekomst af det primære effektendepunkt (kardiovaskulær død, myokardieinfarkt eller apopleksi)
Figure 1: Time to First Occurrence of Primary Efficacy Endpoint (CV death, MI or stroke)
Figur 1: Ændringer i lungedensitet (TLC) fra baseline i RAPID-studiet og RAPID- forlængelsesstudiet
Figure 1: Changes in Lung Density (TLC) from baseline in the RAPID and RAPID Extension studies
Figur 1:Samlet overlevelse i henhold til behandling
Figure 1: Overall survival according to treatment
Figur 1a Figur 1b Figur 1c Figur 1d
Figure 1a Figure 1b Figure 1c Figure 1d
Figur 2
Figure 4
Figur 2 - Analyse af det primære kliniske sammensatte endepunkt for CV-dødsfald, MI og apopleksi (PEGASUS)
Figure 2 - Analysis of primary clinical composite endpoint of CV death, MI and stroke (PEGASUS)‌
Figur 2 - Kaplan-Meier kurve for progressionsfri overlevelse
Figure 2 - Kaplan-Meier curves of progression-free survival
Figur 2 ACR20-respons i PsA-studie 2 over tid op til uge 24
Figure 2 ACR20 response in PsA Study 2 over time up to Week 24
Figur 2 Figur 3
Figure 2 Figure 3
Figur 2 Gennemsnitlig HbA1c (%) efter behandlingsuge hos patienter med type 2-diabetes mellitus, der var utilstrækkeligt kontrolleret på sulfonylurinstof alene eller i kombination med metformin
Figure 2 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on sulphonylurea alone or in combination with metformin
Figur 2 Gennemsnitlig ændring i synsstyrke fra udgangsværdien over tid i studie D2301(RESTORE)
Figure 2 Mean change in visual acuity from baseline over time in study D2301 (RESTORE)
Figur 2 Kaplan-Meier-kurve over interimdata for den samlede overlevelse ved recidiveret myelomatosea
Figure 2 Kaplan-Meier curve of interim overall survival in relapsed multiple myelomaa
Figur 2 Kaplan-Meier-kurve over samlet overlevelse
Figure 2 Kaplan-Meier Curve of Overall Survival
Figur 2 Progressionsfri overlevelse (CA209067)
Figure 2 Progression-free survival (CA209067)
Figur 2 RADIANT-3 – Kaplan-Meier-kurver for progressionsfri overlevelse (radiologisk vurdering af investigator)
Figure 2 RADIANT-3 – Kaplan-Meier progression-free survival curves (investigator radiological review)
Figur 2 Studie 19: Kaplan-Meier-plot af OS hos BRCA-muterede patienter (52 % modenhed)
Figure 2 Study 19: Kaplan-Meier plot of OS in BRCA-mutated patients (52% maturity)
Figur 2 – Revertering af dabigatran-induceret forhøjede koagulationsparametre udtrykt som aPTT hos 90 patienter fra RE-VERSE AD-studiet
Figure 2 – Reversal of dabigatran-induced clotting time prolongation determined by aPTT in 90 patients from the RE-VERSE AD study
Figur 2.
Picture 2.
Figur 2: ACR-respons for fire behandlingsserier (24 uger efter hver behandlingsserie (inden for patient og besøg) hos patienter med et utilstrækkeligt respons over for TNF- hæmmere (n=146)
Figure 2: ACR responses for 4 treatment courses (24 weeks after each course (within patient, within visit) in patients with an inadequate response to TNF-inhibitors (n=146)
Figur 2: Behandlingsvarighed for tidligere behandlede patienter med tidligere partial response eller null response
Figure 2: Duration of treatment for previously treated patients with prior partial or prior null response
Figur 2: Den gennemsnitlige ændring af visus fra baseline til uge 76/100 for behandlingsgrupperne i COPERNICUS OG GALILEO studierne (komplet analysesæt)
Figure 2: Mean Change from Baseline to Week 76/100 in Visual Acuity by Treatment Group for the COPERNICUS and GALILEO Studies (Full Analysis Set)
Figur 2: Gennemsnitlig ugentlig score for sværhedsgrad af kløe over tid, studie 1 (mITT population)
Figure 1: Mean weekly itch severity score over time, study 1 (mITT population)
Figur 2: Kaplan-Meier kurver for progressionsfri overlevelse
Figure 2: Kaplan-Meier curves of Progression-Free Survival
Figur 2: Kaplan-Meier-kurve af total overlevelse (ITT-population)
Figure 2: Kaplan-Meier Curve of Overall Survival (ITT Population)
Figur 2: Kaplan-Meier-kurve for OS pr. behandlingsgruppe i LUX-Lung 8
Figure 2: Kaplan-Meier Curve for OS by treatment group in LUX Lung 8
Figur 2: Kaplan-Meier-kurve for progressionsfri overlevelse (ITT-population) i PCYC-1115-CA-studiet
Figure 2: Kaplan-Meier curve of progression-free survival (ITT Population) in Study PCYC-1115-CA
Figur 2: Kaplan-Meier-kurve som illustrerer den progressionsfrie overlevelse bedømt ved en uafhængig vurdering af den behandlingsnaive patientpopulation (VEG105192)
Figure 2: Kaplan-Meier curve for progression-free survival by independent assessment for the treatment-naïve population (VEG105192)
Figur 2: Kaplan-Meier-kurver for opdateret analyse af samlet overlevelse i studiet MEK116513
Figure 2: Kaplan-Meier curves Updated OS analysis for Study MEK116513
Figur 2: Kaplan-Meier-kurver for progressionsfri overlevelse i hver behandlingsarm i KEYNOTE-006 (intent to treat-population)
Figure 2: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-006 (intent to treat population)
Figur 2: Kaplan-Meier-kurver for samlet overlevelse
Figure 2: Kaplan-Meier curve of overall survival
Figur 2: Klinisk betydningsfuld smertelindring - PecFent versus placebo: % patientepisoder med ≥ 2 points reduktion i smerteintensitet
Figure 2: Clinically Meaningful Pain Relief – PecFent vs placebo: % Patients’ Episodes With ≥2 Point Reduction in Pain Intensity
Figur 2: Opdateret analyse af samlet overlevelse baseret på undergruppe: Hazard ratio og 95 % konfidensinterval i PREVAIL-studiet (intent-to-treat-analyse)
Figure 2: Updated Overall Survival Analysis by Subgroup: Hazard Ratio and 95% Confidence Interval in the PREVAIL Study (Intent-to-Treat Analysis)
Figur 2: Samlet overlevelse
Figure 2: Overall survival
Figur 2a Figur 2b
Figure 2a Figure 2b
Figur 3
Figure 5
figur 3 a
figure 3a
figur 3 b
figure 3b
Figur 3 Gennemsnitlig HbA1c (%) efter behandlingsuge hos patienter med type 2-diabetes mellitus, der var utilstrækkeligt kontrolleret med GLP-1 receptoragonister
Figure 3 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on GLP-1 receptor agonists
Figur 3 Kaplan-Meier-kurver over den samlede overlevelse (OS – ad hoc-analyse den 20. maj 2013)
Figure 3 Kaplan-Meier curves of overall survival (OS –ad hoc analysis 20 May 2013)
Figur 3 – Plasmaniveauer af ubundet dabigatran i den repræsentative gruppe med raske frivillige (administration af idarucizumab eller placebo ved 0 t)
Figure 3 – Plasma-levels of unbound dabigatran in the representative group of healthy subjects (administration of idarucizumab or placebo at 0 h)
Figur 3: Kaplan-Meier kurver for samlet overlevelse
Figure 3: Kaplan-Meier curves of Overall Survival
Figur 3: Kaplan-Meier-kurve for samlet overlevelse (ITT-population) i PCYC-1115-CA- studiet
Figure 3: Kaplan-Meier curve of overall survival (ITT Population) in Study PCYC-1115-CA
Figur 3: Kaplan-Meier-kurve som illustrerer den progressionsfrie overlevelse bedømt ved en uafhængig vurdering af den cytokin-behandlede patientpopulation (VEG105192)
Figure 3: Kaplan-Meier Curve for progression-free survival by independent assessment for the cytokine pre-treated population (VEG105192)
Figur 3: Kaplan-Meier-kurver for progressionsfri overlevelse i hver behandlingsarm i KEYNOTE- 002 (intent to treat-population)
Figure 3: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-002 (intent to treat population)
Figur 3: Kaplan-Meier-kurver over radiografisk progressionfri overlevelse i PREVAIL-studiet (intent-to-treat-analyse)
Figure 3: Kaplan-Meier Curves of Radiographic Progression-Free Survival in the PREVAIL Study (Intent-to-Treat Analysis)
Figur 3: Progressionsfri overlevelse i forhold til PD-L1-ekspression: 5% cut-off (CA209067)
Figure 3: Progression-free survival by PD-L1 expression: 5% cutoff (CA209067)
figur 3a
figure 3a
Figur 4 Figur 5
Figure 4 Figure 5
Figur 4 Figur 5 Figur 6
Figure 4 Figure 5 Figure 6
Figur 4 Gennemsnitlig ændring i forhold til baseline-BCVA over tid til måned 6 og måned 12 (CRUISE)
Figure 4 Mean change from baseline BCVA over time to Month 6 and Month 12 (CRUISE)
Figur 4 Kaplan-Meier-kurve over interimdata for den samlede overlevelse ved recidiveret myelomatose, studie 2011-003
Figure 4 Kaplan-Meier curve of interim overall survival in relapsed multiple myeloma study 2011-003
Figur 4 – Revertering af dabigatran-induceret forhøjede koagulationsparametre udtrykt som dTT i den repræsentative gruppe med raske frivillige (administration af idarucizumab eller placebo ved 0 t)
Figure 4 – Reversal of dabigatran-induced clotting time prolongation determined by dTT in the representative group of healthy subjects (administration of idarucizumab or placebo at 0 h)
Figur 4: Gennemsnitlig ændring af BCVA målt ved ETDRS-bogstavsscoring fra baseline til uge 100 i VIVIDDME- og VISTADME-studierne
Figure 4: Mean Change in BCVA as Measured by ETDRS Letter Score from Baseline to Week 100 in VIVIDDME and VISTADME Studies
Figur 4: Gennemsnitlig ændring i serumfrie insulinkoncentrationer (μE/ml) efter inhalation af 4 mg humant insulin eller subkutan injektion af 12 E hurtigtvirkende humant insulin hos overvægtige forsøgspersoner med type 2 diabetes.
Figure 4: Mean changes in serum free insulin concentrations (µ U/mL) after inhalation of 4mg of human insulin or subcutaneous injection of 12 IU fast-acting human insulin in obese subjects with type 2 diabetes.
Figur 4: Kaplan-Meier-kurve for progressionsfri overlevelse (ITT-population) i PCYC-1112- CA-studiet
Figure 4: Kaplan-Meier curve of progression-free survival (ITT Population) in Study PCYC-1112- CA
Figur 4: Kaplan-Meier-kurve som illustrerer progressionsfri overlevelse bedømt ved en uafhængig vurdering af den samlede patientpopulation (VEG108844)
Figure 4: Kaplan-Meier Curve for progression-free survival by independent assessment for the overall population (VEG108844)
Figur 4: Kaplan-Meier-kurver for samlet overlevelse i AFFIRM-studiet (intent-to-treat-analyse)
Figure 4: Kaplan-Meier Overall Survival Curves in the AFFIRM Study (Intent-to-Treat Analysis)
Figur 4: Kaplan-Meier-kurver for samlet overlevelse i hver behandlingsarm i KEYNOTE-010- studiet (patienter med PD-L1-ekspression TPS  1%, intent to treat-population)
Figure 4: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-010 (patients with PD-L1 expression tumour proportion score  1%, intent to treat population)
Figur 4: Landmark plot for total overlevelse for dasatinib ved BCR-ABL-niveau ( 10% eller
Figure 4: Landmark plot for overall survival for dasatinib by BCR-ABL level ( 10% or
Figur 4: Progressionsfri overlevelse i forhold til PD-L1-ekspression: 1% cut-off (CA209067)
Figure 4: Progression-free survival by PD-L1 expression: 1% cutoff (CA209067)
figur 5
figure 5
Figur 5
Figure 6
Figur 5 Figur 6
Figure 5 Figure 6
Figur 5 Gennemsnitlig ændring fra baseline-BCVA over tid til måned 12 (RADIANCE)
Figure 5 Mean change from baseline BCVA over time to Month 12 (RADIANCE)
Figur 5 RECORD-1 – Kaplan-Meier-kurver for progressionsfri overlevelse (uafhængig central vurdering)
Figure 5 RECORD-1 – Kaplan-Meier progression-free survival curves (independent central review)
Figur 5 – Revertering af dabigatran-induceret forhøjede koagulationsparametre udtrykt som ECT i den repræsentative gruppe med raske frivillige (administration af idarucizumab eller placebo ved 0 t)
Figure 5 – Reversal of dabigatran-induced clotting time prolongation determined by ECT in the representative group of healthy subjects (administration of idarucizumab or placebo at 0 h)
Figur 5: Kaplan-Meier kurver for OS (CA209017)
Figure 5: Kaplan-Meier curves of OS (CA209017)
Figur 5: Kaplan-Meier-estimat af samlet overlevelse, inddelt efter randomiseret behandlingsarm for sygdomsstadie IIIB/IIIC/stadie IVM1a (eksploratorisk delgruppeanalyse)
Figure 5: Kaplan-Meier estimate of overall survival by randomised treatment arm for disease stage IIIB/IIIC/ stage IVM1a (exploratory subgroup analysis)
Figur 5: Kaplan-Meier-kurve som illustrerer progressionsfri overlevelse ved STS bedømt ved en uafhængig vurdering af den samlede patientpopulation (VEG110727)
Figure 5: Kaplan-Meier Curve for Progression-Free Survival in STS by Independent Assessment for the Overall Population (VEG110727)
Figur 5: Samlet overlevelse baseret på undergruppe i AFFIRM-studiet – Hazard Ratio og 95 % konfidensinterval
Figure 5: Overall Survival by Subgroup in the AFFIRM Study – Hazard Ratio and 95% Confidence Interval